Gastrin-cholecystokinin sub receptor expression in AGS cells is associated with direct inhibition and indirect stimulation of cell proliferation via paracrine activation of the epidermal growth factor receptor

A Varro, P J Noble, L E Wroblewski, L Bishop, G J Dockray

Background: Activation of the gastrin-cholecystokinin sub (CCK sub) receptor stimulates cell proliferation and increases production of ligands for the epidermal growth factor receptor (EGF-R).

Aims: To determine the role of gastrin-CCK sub activation in stimulation of cell proliferation via paracrine activation of EGF-R.

Methods: AGS cells were transfected with the gastrin-CCK sub receptor (AGS-G sub cells) or with green fluorescent protein (AGS-GFP cells). Proliferation was determined by [3H] thymidine incorporation, flow cytometry, and cell counting.

Results: Gastrin inhibited proliferation of AGS-G sub cells by delaying entry into S phase. However, when AGS-G sub cells were cocultured with AGS-GFP cells, gastrin stimulated proliferation of the latter. Immunohistochemical and pharmacological studies using metalloproteinase and kinase inhibitors indicated that the proliferative response was mediated by paracrine stimulation of EGF-R and activation of the mitogen activated protein kinase pathway through release of heparin binding EGF.

Conclusions: Gastrin can directly inhibit, and indirectly stimulate, proliferation of gastric AGS cells.

It is well recognised that the gastric hormone gastrin stimulates gastric epithelial cell proliferation as well as acutely regulating acid secretion. Elevated plasma gastrin concentrations are associated with increased parietal cell mass, hyperplasia of histamine producing enterochromaffin-like (ECL) cells, and increased labelling of proliferating cells by bromodeoxyuridine. Gastrin precursor peptides (progastrin and Gly-gastrin) are thought to stimulate proliferation of normal and neoplastic colon cells although the receptor at which they act is still uncertain. In contrast, proliferation of gastric epithelial cells is thought to be primarily regulated by the amidated gastrins at the gastrin-cholecystokinin sub (CCK sub) receptor. The picture is complicated however by reports that in some cell lines expression of the gastrin-CCK sub receptor is associated with inhibition of proliferation. Moreover, in the normal gastric epithelium, it is not clear that the gastrin-CCK sub receptor is expressed by proliferating cells, aside from ECL cells. It is however recognised that gastrin increases production of ligands for the epidermal growth factor receptor (EGF-R). The extent to which the proliferative effects of gastrin might be indirect and secondary to release of EGF-R ligands remains uncertain. In the present study we have developed a coculture system which allows study of both the direct effects of gastrin (mediated by cells expressing the receptor) and indirect effects mediated through paracrine release of secondary mediators. We report here that expression of the gastrin-CCK sub receptor is linked to direct inhibition of proliferation of cells expressing the receptor (AGS-G sub cells), and to indirect stimulation of proliferation of cocultured cells that do not express the receptor (AGS-GFP cells).

METHODS

Tissue culture and transfection

AGS cells were cultured in HAMS/F12 medium supplemented with 10% fetal bovine serum (FBS) and 1% w/v penicillin/ streptomycin (Life Technologies, Paisley, UK). Cells stably transfected with full length cDNA encoding the human gastrin-CCK sub receptor, or with the empty vector, were generated as previously described. In addition, AGS cells stably expressing green fluorescent protein (AGS-GFP cells) were generated by transfection with pEGFP-C1 (Clontech, Basingstoke, UK) using TransFast reagent (Promega, Southampton, UK), and clones resistant to G418 (Life Technologies) selected by fluorescence microscopy. Cells were counted by a haemocytometer and viability determined by trypan blue exclusions (over 95% in all experiments).

Drugs, growth factors, and antibodies

Heptadecapeptide amidated gastrin (that is, G17) was obtained from Peninsula (St Helens, Merseyside, UK); L-740,093 was obtained from Merck (Harlow, UK). Ro-32-0432, GM6001, AG1478, and BB2516 were obtained from Calbiochem (Nottingham, UK). Phorbol-12-myristate-13-acetate (PMA), CRM197, transforming growth factor α (TGF-α), and heparin binding (HB)-EGF were obtained from Sigma (Poole, Dorset, UK); neutralising goat HB-EGF antibody from RDI (Flanders, New Jersey, USA). Mouse monoclonal antibody to phospho- mitogen activated protein (MAP) kinase was obtained from NEB (Hitchin, Herts, UK), and phycoerythrin conjugated goat antimouse gamma globulin was obtained from Sigma.

Abbreviations: CCK, cholecystokinin; ECL, enterochromaffin-like cell; EGF, epidermal growth factor; EGF-R, epidermal growth factor receptor; FBS, fetal bovine serum; GFP, green fluorescent protein; HB-EGF, heparin binding EGF; G17, heptadecapeptide gastrin; MAP, mitogen activated protein; PBS, phosphate buffered saline; PKC, protein kinase C; PMA, phorbol 12-myristate-13-acetate; TGF-α, transforming growth factor α.
[**H**] Thymidine incorporation

Synthesis of DNA was assessed by incorporation of [**H**] thymidine (Amersham, Little Chalfont, Bucks, UK). Cells (5×10⁴) were cultured in six well plates in 2 ml of medium containing 10% FBS with or without G17 (10 pM to 10 nM) for up to 96 hours. Alternatively, cells were cultured in 2 ml of medium containing 10% FBS for 24 hours and were then synchronised in G0/G1 by incubation in serum free medium for 48 hours. Progression through S phase was stimulated by addition of medium containing 10% FBS with or without G17 (10 pM to 10 nM), PMA (10–100 nM), or TGF-α (10 ng/ml). Cells were then incubated for one hour with 2 µCi [**H**] thymidine and washed three times in 2 ml of ice cold phosphate buffered saline (PBS). Trichloroacetic acid (2 ml, 5%) was added and dishes were incubated at 4°C for 20 minutes; cells were washed twice with 2 ml of ice cold ethanol, DNA solubilised in 1 ml of 0.1 M NaOH (60 minutes, 60°C), and an aliquot taken for scintillation counting.

Flow cytometry

In initial experiments on subconfluent AGS-G₂ cells, cultures were washed in PBS, cells harvested using trypsin, fixed in 70% ethanol, and treated with 100 µg/ml RNasea (Sigma, Poole, UK). Cellular DNA was stained with 20 µg/ml propidium iodide (Sigma) and quantified by cytometry using a Becton Dickinson FacScan (Becton Dickinson, Cowley, Oxford, UK). Cell cycle analysis was performed using Modifit Software (Verity Software House Inc.). In experiments on cocultures of AGS-G₂ and AGS-G₃ cells were recovered with trypsin, washed once in PBS, resuspended in PBS containing 2 µg/ml Hoechst 33342 (Molecular Probes, Leiden the Netherlands), and incubated for 30 minutes at 37°C prior to analysis by flow cytometry using a Becton Dickinson FACScan Vantage. Signals were gated for GFP fluorescence using excitation at 488 nm and emission at 510 nm. Hoechst 33342 fluorescence was detected by excitation at 355 nm and emission at 424 nm. Cell cycle data were analysed using Modifit Software running on an Apple powermac G4 computer.

Proliferation of AGS-G₂ cells

Cocultures of 10⁵ AGS-G₂ and AGS-G₃ cells were plated in full media in 12 well plates. After 24 hours, cells were washed and incubated in serum free media with and without gastrin for up to 72 hours. Media was replaced with 0.5 ml of PBS, and fluorescence counted in a FluoroCount Plate Reader (Packard, Brook House, Pangbourne, Berks, UK) with an excitation wavelength of 485 nm and an emission wavelength of 510 nm.

Phospho-MAP kinase detection

Phospho-MAP kinase was detected by the method recently described by Chow and colleagues. Brieﬂy, cocultures of AGS-G₂ and AGS-G₃ cells were washed with PBS, recovered with trypsin, pelleted, resuspended in 2% paraformaldehyde, incubated for 10 minutes at 37°C, and then transferred onto ice for two minutes. Ice cold 100% methanol was added to the cells to give a final concentration of 90% and the cells were kept on ice for a further 30 minutes after which they were either labelled immediately or stored at ~20°C in 90% methanol. For labelling, cells were washed in PBS containing 4% v/v FB and then incubated with antibody to phospho-MAP kinase (1:200) for 15 minutes at room temperature, washed once with PBS in 4% FBS, and then labelled with secondary antibody (phycoerythrin conjugated goat antimouse gamma globulin (1:100)) for 15 minutes at room temperature. Cells were then washed once with PBS containing 4% FBS and resuspended in PBS prior to FACS analysis. GFP fluorescence was used for 10 described above. Kinase detected from the phycocrythin conjugated secondary antibody using excitation at 488 nm and emission at 575 nm.

Antisense treatment

Cells were preincubated for 24 hours with either random or EGF-R antisense oligonucleotides (Biognostik, Gottingen, Germany) before addition of gastrin. Uptake indicated by FITC labelled oligonucleotides was more than 80% after 24 hours.

Western blotting

Cells were stimulated with gastrin (1 nM, up to 24 hours), extracted in lysis buffer and western blotting was performed as previously described using a goat anti-HB-EGF antibody (Santa Cruz, California, USA).

Statistics

Results are presented as means (SEM); comparisons were made using a t test and were considered significant at p<0.05.

RESULTS

Expression of the gastrin-CCK₉ receptor is linked to inhibition of proliferation

To examine the effect of expression of the gastrin-CCK₉ receptor on proliferation of AGS cells, we determined cell numbers and incorporation of [**H**] thymidine in cells stably expressing the receptor. In the presence of 1 nM G17 for 72 hours, cell numbers did not increase compared with controls but suppression of proliferation was reversed by the gastrin-CCK₉ receptor antagonist L-740,093 100 nM (fig 1A). Gastrin had no effect on either the parental cell line (fig 1A) or AGS cells stably transfected with the empty vector (not shown). When AGS-G₂ cells were incubated in media containing 10% FBS, G17 produced a time dependent inhibition of [**H**] thymidine incorporation (fig 1B). This response was related to the concentration of gastrin and was detectable with gastrin concentrations in the physiological range (that is, <100 pM) (fig 1C). When AGS-G₂ cells were synchronised in the G1 phase of the cell cycle by incubation in serum free medium for 48 hours, [**H**] thymidine incorporation was reduced by over 90%. Introduction of 10% FBS increased [**H**] thymidine incorporation after 12–15 hours (corresponding to cells entering S phase) and this was inhibited by G17 (fig 1D).

Expression of the gastrin-CCK₉ receptor is linked to arrest in G1 phase of cell cycle

To characterise the effects of gastrin-CCK₉ receptor expression on progression through the cell cycle, we used flow cytometry. Addition of 10% serum to cells incubated in serum free medium for 24 hours significantly increased the proportion of cells in S phase (20.1 (3.1)% compared with controls; p<0.05) (fig 2A, B). Addition of gastrin completely inhibited the effect of serum (fig 2C). Similarly, the protein kinase C stimulant PMA arrested AGS cells in the G1 phase of the cell cycle (fig 2D), and similar to gastrin inhibited [**H**] thymidine incorporation (19.9 (6.2)% compared with controls; p<0.05).

Gastrin-CCK₉ receptor expression is linked to paracrine stimulation of proliferation

Gastrin stimulates the production of multiple paracrine mediators in vivo, including EGF-R ligands, histamine, Reg, and somatostatin. To determine the effects of paracrine mediators on proliferative responses to gastrin, we cocultured cells expressing the gastrin-CCK₉ receptor (AGS-G₂ cells) with cells expressing GFP but not the gastrin receptor (AGS-G₂ cells). There was a linear relationship between fluorescence and AGS-G₂ cell number (fig 3A). Interestingly, in cocultures of AGS-G₂ and AGS-G₃ cells under serum free conditions, gastrin increased the numbers of AGS-G₂ cells while the numbers of AGS-G₃ cells remained constant. The increase in AGS-G₂ cell number was dependent on time and the concentration of gastrin, and was detectable with concentrations in the physiological range (fig 3B–D). To determine the effect of gastrin on progression of cocultured cells through the
cell cycle, we used flow cytometry to quantify cells labelled with Hoechst 33342. In the case of AGS-GR cells, gastrin increased the proportion of cells in G0/G1 and decreased cells in S phase (p<0.05). In contrast, in the case of AGS-GFP cells in the same cultures, there was a decrease in the proportion of cells in G0/G1 and an increase in S phase (fig 3E, F).

Expression of the gastrin-CCK<sub>4</sub> receptor is linked to release of an EGF-R ligand

To determine whether stimulation of EGF-R might mediate the effect of gastrin-CCK<sub>4</sub> receptor activation, we first confirmed that the EGF-R ligand TGF-α stimulated [³H] thymidine incorporation into cells synchronised in G0/G1 phase by incubation in serum free medium (control 100 (3.4); TGF-α 10 ng/ml for 16 hours 245.0 (5.5)%; p<0.01). Similarly, TGF-α stimulated proliferation of AGS-GFP cells in the system described above (control 100 (4.2); TGF-α 221 (10.2)%; p<0.05). We then studied how the proliferative response to gastrin of AGS-GFP cells in coculture with AGS-GR cells was influenced by (A) AG-1478 which inhibits EGF-R tyrosine kinase activity, (B) neutralising antibody to EGF-R, and (C) antisense inhibition of EGF-R expression. All three treatments significantly inhibited the

Figure 1  Inhibition of proliferation of cells expressing the gastrin-cholecystokinin<sub>4</sub>, receptor. (A) The number of wild-type AGS cells was not changed by incubation in 1 nM heptadecapeptide gastrin [G17] for 72 hours but G17 inhibited the increase in AGS-GR cell numbers and this was reversed by L-740,093 (100 nM). (B) Incorporation of [³H] thymidine into AGS-GFP cells was decreased by incubation with G17 for up to 72 hours, and (C) by G17 in concentrations of 300 pM to 10 nM. (D) In cells synchronised in the G1 phase of the cell cycle by incubation in serum free medium for 48 hours, addition of 10% fetal calf serum increased [³H] thymidine incorporation after 12–15 hours, and this was inhibited by G17. Means (SEM), n=4 – 8. *p<0.05 compared with controls.

Figure 2  FACS analysis of AGS-G<sub>4</sub> cells. (A) Control incubation in serum free medium. (B) Cells cultured in serum free medium for 48 hours followed by 12 hours in 10% fetal calf serum showing progression into S phase. (C) Incubation with heptadecapeptide gastrin [G17 10 nM] blocked progression into S phase in synchronised cells, and (D) phorbol-12-myristate-13-acetate (100 nM) also inhibited progression into S phase. Means (SEM), n=4.
HB-EGF receptor and to block proliferative responses to diphtheria toxin mutant CRM197 which is known to act as an proliferative response of AGS-GFP cells was also inhibited by the assessed if gastrin increased p42/44 MAP kinase phosphoryla-

As stimulation of EGF-R is linked to increased MAP kinase, we 

Figure 3  Proliferation of AGS-GFP cells in coculture with AGS-GR cells. (A) Fluorescence (cps) of AGS-GFP cells was linearly related to cell number (coefficient of correlation 0.985; p<0.05). (B) In cocultures, heptadecapeptide gastrin (G17 1 nM) stimulated a time dependent increase in the numbers of AGS-GFP cells, and (C) this effect of G17 was concentration dependent. (D) In cocultures, G17 (1 nM) increased the numbers of AGS-GFP cells but not AGS-GR cells, determined by cytometry. Flow cytometry of cocultured AGS-G2 and AGS-GFP cells incubated with gastrin showed (E) increased abundance of AGS-G2 cells in G0/G1 and decreased numbers in S phase, while (F) there was a decrease in AGS-GFP cells in G0/G1 and an increase in S phase. Means (SEM), n=4–8. *p<0.05 versus control.

effect of gastrin on ASG-GFP cell proliferation indicating a role for the EGF-R in this response (fig 4A).

Proliferative responses following expression of the gastrin-CCK2 receptor are linked to metalloproteinase activity

Shedding of EGF-R ligands from the cell surface is thought to depend on metalloproteinase activity that can be stimulated by protein kinase C (PKC). We found that the PKC inhibitor Ro-32-0432 reduced the proliferative response of AGS-GFP cells to gastrin when cocultured with AGS-G2 cells. Moreover, two metalloproteinase inhibitors, BB2516 and GM6001, also reversed gastrin stimulated proliferative responses (fig 4B), compatible with PKC dependent release of an EGF-R ligand.

We then examined the effect of neutralising antibodies to two EGF-R ligands, TGF-α and HB-EGF. Antibody to the latter, but not the former, substantially inhibited the proliferative response of AGS-GFP cells when cocultured with AGS-G2 cells. The proliferative response of AGS-GFP cells was also inhibited by the diphtheria toxin mutant CRM197 which is known to act as an HB-EGF receptor and to block proliferative responses to HB-EGF (fig 4C). Direct evidence that gastrin increased HB-EGF production was provided by the finding that the abundance of the HB-EGF precursor detected by western blot was increased in gastrin stimulated cultures by four hours (fig 4D).

Gastrin stimulates MAP kinase both directly and indirectly

As stimulation of EGF-R is linked to increased MAP kinase, we assessed if gastrin increased p42/44 MAP kinase phosphoryla-
tion in AGS-GFP cells in coculture with AGS-G2. Using flow cytometry of fixed, permeabilised, cocultured cells incubated with gastrin, and detection of phosphorylated p42/44MAP kinase by specific antibody, we found that in both cell lines there was gastrin dependent stimulation of MAP kinase that peaked at 30 minutes (fig 5).

DISCUSSION

Our results showed that expression of the gastrin-CCK2 receptor is associated with both stimulation and inhibition of cell proliferation. In cells expressing the receptor, gastrin inhibited proliferation. However, when these cells were cocultured with cells not expressing the receptor, gastrin stimulated proliferation of the latter. We present evidence that the proliferative response was attributable to paracrine stimulation of EGF-R and that this stimulation required release of HB-EGF as a consequence of metalloproteinase activity.

There is abundant evidence to suggest that gastrin stimulates proliferation of gastric mucosal cells. In the case of the ECL cell, this may be a direct mitogenic effect. In general however it is not clear whether mitogenic responses to gastrin in the stomach are direct or reflect indirect effects mediated by other growth factors. Studies in cell lines indicate both stimulation and inhibition of proliferation in response to gastrin-CCK2 receptor activation. Precisely how these different responses might be determined is unclear. Thus in several cells lines, including AR4-2J cells, small cell lung cancer cells, and Rat-1 cells expressing this receptor, there is increased proliferation in response to gastrin-CCK2 receptor
However, in some pancreatic cell lines and CHO cells, expression of the gastrin-CCKB receptor is linked to inhibition of proliferation. This receptor is coupled to Gαq/11, and other receptors signalling through Gαq/11 (for example, the muscarinic M3 receptor) have also been found to both stimulate and inhibit cell proliferation depending on cellular context.

In addition to variation between cell lines, there may be differences between clones of the same cell line as in some AGS cell clones G17 is reported to stimulate AGS cell proliferation. The parental cell line used for the present study did not express gastrin-CCKB receptors and did not respond to gastrin. Some AGS cell clones may express the gastrin gene but as these cells cannot process the product to mature gastrin this does not result in the release of a ligand for the gastrin-CCKB receptor.

It is well established that stimulation of G protein coupled receptors, such as the gastrin-CCKB receptor, can lead to phosphorylation of EGF-Rs, which in turn leads to activation of the MAP kinase pathway and proliferation. In some systems this is attributable to an intracellular, or direct, signalling pathway possible due to PKC activation of Ras via recruitment of SoS-Grb2 complexes. In other cases however it now seems likely that G protein coupled receptor stimulation leads to increased intracellular calcium or activation of PKC which leads to release of growth factors by proteolysis of membrane associated precursors, and subsequent stimulation of EGF-R. However, the relative importance of this type of event in mediating proliferative responses to G protein coupled receptor stimulation remains uncertain. The combined results of using specific HB-EGF antibodies, a
mutant diphtheria toxin that binds HB-EGF, and metallo-proteinase inhibitors, clearly indicate that proliferative responses of AGS cells following gastrin-CCK receptor activation require cleavage of HB-EGF. The data therefore support the idea that proliferative responses are due to activation of a paracrine stimulant of cells adjacent to those expressing the gastrin-CCK receptor, and are not simply due to autocrine stimulation. The shedding HB-EGF is stimulated by PKC so that PKC inhibitors reverse proliferative responses. The system is complex however because in AGS cells and in other cell types, activation of PKC by phorbol esters leads to arrest in the G1 phase of the cell cycle. It therefore appears that activation of PKC leads to direct inhibition of proliferation and indirect (HB-EGF mediated) stimulation of proliferation. As our data show that there is activation of the MAP kinase pathway in both AGS and GFP-G cells, it would appear that in the receptor expressing cells the pathway associated with inhibition of proliferation dominates.

There is growing interest in the role of gastrin and related peptides as growth factors in gastrointestinal cancer. The gastrin gene encodes multiple putative growth factors including progastrin itself, the Gly-gastrins, and the amidated peptides as growth factors in gastrointestinal cancer. The references for this include: 8-10

ACKNOWLEDGEMENTS

This work was supported by grants from the Medical Research Council. We are grateful to Drs C Thompson and M Jones for assistance with flow cytometry, and Cathy McLean for skilled technical assistance.

Authors’ affiliations

A Varro, P J Noble, L E Wroblewski, L Bishop*, G J Dockray, Physiological Laboratory, University of Liverpool, Liverpool UK.

*Present address: Department of Pathology, Lancaster Royal Infirmary, Lancaster, UK.

REFERENCES